ASCENTAGE-B (06855) was showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting, presenting four clinical advancements and demonstrating the potential of combination therapies.

ASCENTAGE-B (06855) announced that the company will present four preclinical research results in poster form at the American Association for Cancer Research (AACR) Annual Meeting in 2026. The conference will be held in San Diego, California from April 17 to April 22, 2026. The posters will cover three different products from the company, including: the novel BCR-ABL inhibitor orelabtinib (trade name: Nalatinib; development code: HQP1351), the FAK/ALK/ROS1 triplet tyrosine kinase inhibitor APG-2449, and the PRC2/EED inhibitor APG-5918. Of note, the presentation will showcase the potential of orelabtinib beyond chronic myelogenous leukemia (CML), including its new applications in endometrial cancer (EC), mantle cell lymphoma (MCL), and combination therapy with BTK inhibitors. Additionally, the research on APG-2449 for BRAF mutant tumors and APG-5918 for small cell lung cancer demonstrates the company's strategic focus on overcoming resistance mechanisms and exploring combination therapy strategies.